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Gene delivery in the equine cornea: a novel therapeutic strategy
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Abstract
Objective—To determine if hybrid adeno-associated virus serotype 2/5 (AAV5) vector can
effectively deliver foreign genes into the equine cornea without causing adverse side effects. The
aims of this study were to: (i) evaluate efficacy of AAV5 to deliver therapeutic genes into equine
corneal fibroblasts (ECFs) using enhanced green fluorescent protein (EGFP) marker gene and (ii)
establish the safety of AAV5 vector for equine corneal gene therapy.
Animal Material—Primary ECF cultures were harvested from healthy donor equine corneas.
Cultures were maintained at 370C in humidified atmosphere with 5% CO2.
Procedure—AAV5 vector expressing EGFP under control of hybrid cytomegalovirus (CMV) +
chicken β-actin (CBA) promoter was applied topically to ECF. Expression of delivered EGFP
gene in ECF was quantified using fluorescent microscopy. Using DAPI staining, the total number
of cells and transduction efficiency of tested AAV vector was determined. Phase contrast
microscopy, trypan blue and TUNEL assays were used to determine toxicity and safety of AAV5
for ECFs.
Results—Topical AAV5 application successfully transduced significant numbers of ECFs.
Transduction efficiency was 13.1%. Tested AAV5 vector did not cause phenotype change or
significant cell death and cell viability was maintained.
Conclusions—Tested AAV5 vector is effective and safe for gene therapy in ECFs in vitro.
Clinical Relevance—Tested AAV5 vector has potential to extend a novel gene therapy
approach to treat equine corneal disease in vivo.
Introduction
The cornea is an ideal target tissue for gene therapy because of its accessibility and immune-
privileged nature.1–3 The success of gene therapy is contingent upon two variables: the
vector and the technique employed to deliver a vector into targeted tissue. Multiple viral and
non-viral vectors have been developed for somatic gene therapy. In general, viral vectors
offer several fold higher transduction efficiencies and long-term gene expression compared
to non-viral vectors.1, 2 In the last two decades, efficacy of various viral vectors such as
adeno, adeno-associated (AAV), retro, lenti, and herpes simplex, have been examined for
introducing DNA into corneal cells in vitro, in vivo and ex vivo.1–4 Most of these studies
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used fluorescent or non-fluorescent marker genes to track the level and duration of transgene
expression in cornea.2 Viral vectors have been associated with toxicity and immunogenicity;
however, previous studies have demonstrated AAV to be non-pathogenic and safe for
corneal gene therapy in both the rabbit and mouse.1, 2, 5 To our knowledge no studies have
been conducted to test the efficacy of AAV for the equine cornea.
Corneal disease is a significant cause of decreased or absent vision in horses world-wide.6
Vision loss in a horse frequently results in ocular pain, decreased performance, an increased
safety risk and in some cases, the horse’s very survival. Inflammation of the cornea as the
result of ocular trauma, autoimmune or neoplasia are common causes of decreased corneal
transparency.7 However, corneal ulceration and ocular trauma are the most significant
pathologic entities affecting the equine eye.6 Corneal ulceration, particularly deep corneal
infections can rob a horse of its vision, leaving it unable to fulfill the tasks that they are
asked to complete. Treatment of corneal ulceration can be costly, labor intensive, and
prolonged.8 Conventional treatment of corneal ulceration utilizes topical and systemic
therapeutic agents including antimicrobials/antifungals to eliminate and control infectious
agents, anticollagenases to decrease stromal degradation, mydriatics for ciliary spasm and
stabilization of the blood-aqueous barrier, and non-steroidal anti-inflammatory drugs to
alleviate ocular pain.6, 8, 9 Presently, pharmacological agents effective in the reduction of
corneal fibrosis and specifically used to reduce corneal scarring, thus improving long-term
visual outcome, are not routinely used in the management of equine corneal ulcers in
veterinary medicine.
Numerous studies have demonstrated AAV to be a safe and efficient method for gene
therapy in a variety of tissues.1, 2, 4, 10–12 Among recombinant viral vectors, AAV has
shown the greatest potential for efficient gene delivery into ocular cells.2, 3, 13 AAV can
transduce dividing and non-dividing cells as well as extend long-term transgene expression.2
Although there are more than 100 serotypes of AAV, serotypes 1–9 have been the most
commonly examined for gene therapy14, 15 AAV serotypes 2 and 5 have demonstrated a
varied degree of successful transgene delivery into photoreceptors and retinal pigment
epithelial cells of the rodent, canine and primate in vivo.14, 15 Preclinical and clinical gene
therapy trials have been undertaken for several retinal diseases, including ocular albinism,
retinitis pigmentosa and Leber congenital amaurosis.16–20 Compared to literature reports of
retinal gene therapy, limited studies have been performed to evaluate the usefulness of AAV
vectors in corneal gene therapy. The efficacy of AAV2 and AAV5 to deliver genes into the
corneal stroma of rabbits and rodent in vivo has been established.2
Evidence suggests that the major determinant of cellular tropism and transduction efficiency
of AAV is attributable to the capsid protein.21 Many hybrid AAV vectors have been
engineered using capsid protein of AAV serotypes 1–9. AAV5 has proven superior for
transgene delivery into the retina and cornea compared to AAV2.15 Our ongoing gene
therapy studies in mouse and rabbit corneas have demonstrated that AAV5 and AAV8 are
relatively more efficient at delivering genes into corneal stromal cells compared to AAV2, 6
and 9 serotypes (unpublished data, in press, Brain Research Bulletin). In this study we tested
the hypothesis that AAV5 vector could effectively deliver a foreign gene into ECFs without
causing adverse side effects. Specifically, the aims of this study were to: (i) evaluate
efficacy of AAV5 expressing enhanced fluorescent green protein (EGFP) marker gene for
delivering therapeutic genes into ECFs and (ii) establish the safety of AAV5 vector for
equine corneal gene therapy.
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Equine corneal fibroblast culture
Full-thickness 6-mm axial corneal buttons were aseptically harvested from healthy research
horses undergoing humane euthanasia for reasons unrelated to this study. Slit-lamp
biomicroscopy was performed by a veterinary ophthalmologist (EAG) prior to euthanasia to
insure that harvested corneal tissues were collected from horses free of any anterior segment
disease. Corneal samples were washed with serum-free Dulbecco’s modified Eagles medium
supplemented with antibiotics (penicillin-streptomycin). The epithelium and endothelium
were removed by gentle scraping with a #15 scalpel blade. Using sharp dissection, the
remaining corneal stroma was sub-sectioned into 2mm sections and placed on tissue culture
dishes in a humidified CO2 incubator at 37 degrees Celsius in Dulbecco’s modified Eagles
medium (DMEM) containing 10% fetal bovine serum for several weeks to obtain primary
cultures of ECFs.
AAV vector production
AAV serotype 5 expressing EGFP under control of hybrid cytomegalovirus (CMV) +
chicken β-actin (CBA) promoters (AAV5-pTRUF11-EGFP) was utilized for all experiments
and obtained from Prof. Gregory Schultz and Prof. William Hauswirth, University of
Florida, Gainesville, Florida. Construction of an AAV5 vector containing the enhanced
green fluorescent protein (EGFP) reporter gene was performed according to standard helper-
dependent techniques using adenovirus free system.1
AAV vector and ECF transduction
Seventy-percent confluent cultures of ECFs in 12-well plates were used for all the
experiments. Cultures were serum deprived for 2 hrs prior to viral transduction (viral titer of
109 genomic copies/micro liter) and two microliters of AAV serotype 5 expressing EGFP
marker gene under control of hybrid CMV + CBA promoters were added to ECF cultures
via topical application in serum free medium at a multiplicity of infection (MOI) of 105 and
2 × 105. After 6 hrs, the medium containing viral vector was replaced with fresh serum-
containing medium and the cells were incubated for 2 days prior to microscopic evaluation
of fluorescence.
AAV safety
Light microscopy images were obtained to observe any phenotypic or morphologic changes
in ECF cultures after the application of AAV5.
TUNEL assay was used to detect fibroblast apoptosis due to AAV vector transduction. ECF
cells were fixed in Paraformaldehyde at room temperature for 5 minutes and then washed in
phosphate buffered saline. A fluorescence-based TUNEL assay was used according to the
manufacture’s instructions using ApopTag apoptosis detection kit (Chemicon international,
Temecula, CA, USA). Cellular viability was assessed using a trypan blue (Sigma-Aldrich,
St. Louis, USA) administered 48 hrs after transduction. Trypan blue dye staining dead cells
blue and viable cells staining white were counted microscopically in a hemocytometer.
AAV transduction efficiency
EGFP transduced ECF cells and DAPI-nuclei in culture were counted using direct
fluorescence microscopy at 100X magnification in ten randomly selected, non-overlapping
areas for each treatment. Analysis was performed on a PC computer using the public domain
NIH Image program (developed at the U.S. National Institutes of Health and available on
the Internet at http://rsb.info.nih.gov/nih-image). Percent transduction efficiency was
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calculated by dividing the total number EGFP positive cells by that of the total number of
DAPI stained nuclei.
Statistical Analysis
Results were expressed as mean ± standard error of the mean (SEM). Statistical analysis was
performed using two-way analysis of variance (ANOVA) followed by Bonferroni test for
comparing data between control and AAV vector.
Results
AAV safety
Cultured ECFs demonstrated a classic spindle shaped morphology. No observable changes
in light microscopic morphology were detected at any time point after successful
transduction with AAV5 (Figure 1A–D). Throughout the study period, both the control and
the AAV transduced populations continued to demonstrate a healthy spindle shaped
morphology and progressed normally to confluence.
Trypan blue exclusion assay demonstrated cellular viability of AAV-treated and untreated
ECFs between 96–98% at all three tested time points (8hrs, 24hrs and 48hrs) after AAV
transduction. Recall that transduction efficiency was established at the 48 hour time point.
The results of cellular viability determined with trypan blue assay are shown in Figure 2.
The safety of AAV5 vector for ECF was further established by determining its effects on
cell death with TUNEL assay. No detectable cellular apoptosis was detected using this
method (results not shown).
AAV transduction efficiency
We were able to demonstrate the successful transduction of a foreign gene, EGFP, into ECF
cells with topically applied AAV5 via fluorescent microscopy. Figure 3A–C demonstrates
green fluorescence in a spindle shaped morphology in successfully transduced ECF cells
against the blue DAPI-stained nuclei of the ECF cells. Quantification of this data was
completed at 100x magnification using the previously described method and is displayed in
Figure 3D. This data demonstrates a significant transduction efficiency of 13.1% using
AAV5 in ECF in vitro.
Discussion
Corneal gene therapy represents a novel approach to the potential treatment of a wide
variety of keratopathies. It may provide an opportunity to target the specific underlying
cause of a corneal disorder as opposed to simply treating the symptoms as with conventional
pharmaceuticals. Furthermore, its therapeutic benefits are evident long-term, even after a
single treatment versus the required repeated applications for long periods with conventional
small molecule drug therapy.2 Gene therapy for equine corneal disease is a new application
of this developing technology. Common equine corneal diseases include traumatic,
inflammatory, neoplastic and infectious keratidities. For many of theses conditions,
particularly when severe, therapeutic goals are directed at preserving the globe and relieving
ocular discomfort and to a lesser extent toward re-establishing clear corneal transparency.
Many of these keratidities require labor-intensive treatments which can be difficult for both
horse and owner. Gene therapy could provide an alternative to traditional small molecule
therapy or be used adjunctively to improve corneal transparency and long-term visual
success.
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This is the first study to evaluate the transfection effectively AAV into ECFs. AAV5 was
selected in this study because of its availability, enhanced transgene delivery, and low
cellular toxicity. As this was the initial testing of AAV on ECFs, an in vitro model was used.
In vitro models are economical, practical, easily maintained, and allow the investigator
precision in control of experimental conditions. The transduction efficiency of AAV5
serotype determined in vitro for various cell types such as lung epithelium, skeletal muscle,
gastrointestinal cells, and corneal fibroblasts was similar to that studied in vivo.22, 23, 24
Thus, it is reasonable to conclude that an in vitro model can provide highly relevant and
beneficial information regarding the efficacy of the AAV vector for gene therapy in vivo.25
Based on our earlier in vivo studies performed in mouse and rabbit corneas with selected
AAV5 vector, we speculate that tested AAV5 vector will demonstrate similar gene transfer
efficacy into equine stroma in vivo without causing significant side effects.1, 2 Further
studies examining the potential of selected AAV5 vector to deliver therapeutic genes into
the equine cornea in vivo are warranted.
Many laboratories, including ours, have demonstrated that recombinant AAV2 vectors can
efficiently transport foreign genes in the cornea, retina, and various other ocular
tissues.2, 14, 15 However, enhanced gene transfer has been noted with the hybrid AAV
vectors developed subsequently by combining AAV2 genome with capsid proteins of other
AAV serotypes (1–9). The hybrid AAV vectors were found superior to the conventional
recombinant AAV vectors in regards to transduction efficiency and safety.2, 11, 23, 26 Also,
hybrid vectors demonstrated unique tropism and variable transduction efficiencies for
differing target tissues. For example, AAV 2/9 hybrid vector was more efficient at gene
delivery in cardiac muscle cells compared to AAV2/1, AAV2/6, AAV2/7 and AAV2/8.18
Gao et al27 found that AAV 2/8 had a 200 fold higher transgene delivery into liver cells
compared to AAV2 vector. Interestingly, AAV2/6 hybrid vector was more efficient at gene
delivery into muscle cells than the AAV2/5 or AAV2 vector.22 This pattern of cellular
tropism and subsequent differences in gene efficiency has been documented with AAV in
ocular tissues. The corneal stroma, photoreceptors, and retinal pigmented epithelium showed
higher levels of delivered-gene expression with AAV2/5 compared to the AAV2 vector.15
The current literature suggests that further evaluation using different hybrid AAV vectors
developed by combining AAV2 genome with various AAV serotypes capsids (AAV1-9) for
the ECFs is also warranted.
A transduction efficiency of 13.1% was noted for the ECFs with the tested hybrid AAV2/5
vector in this study. Due to lack of experimental evidences at this point it is unknown
whether this rate of transduction is of therapeutic value for the equine cornea. We
hypothesize that moderate transduction efficiency ranging from 12–20% will be sufficient to
treat corneal diseases in horse. Future investigations will test this hypothesis. Based on the
results of our gene transfer investigations performed in mice and rabbit corneas in vivo, and
human corneas ex vivo we speculate that for achieving maximum gene transduction in the
equine cornea in vivo direct contact of AAV to the stroma for a short duration (2–10
minutes) may be required. AAV applied topically on the mouse or rabbit cornea with intact
epithelium showed considerably low AAV penetration in the stroma compared to the
corneas that received AAV after removing the epithelium1. Also, corneas receiving AAV
after epithelial removal showed transduction predominantly in anterior stroma and minimal
in the posterior stroma. Gene therapy to treat corneal ulceration and scarring is clinically
relevant as most myofibroblast formation is observed in the anterior stroma28 except in the
cases of very severe, deep ulceration. The immunogenicity of tested AAV5 vector in vivo
also needs to be established. Of note, tested AAV5 vector did not cause clinically significant
immune reactions in mouse or rabbit eyes in vivo, suggesting that similar results could be
observed in vivo in horses.2 In this in vitro study, testing of AAV5 resulted in no detectable
adverse effects (i.e. loss of cellular viability, cell death, and/or phenotype change). Future
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studies may examine the effects of different viral concentrations, viral incubation times, and
comparison of the transduction efficiencies of several serotypes.
Gene therapy provides many possible therapeutic options depending on the gene being
transduced. Potential areas of therapy include inserting the decorin gene into ECF.29 The
decorin gene is known to silence the effects of TGFβ, which causes transformation of ECF
to myofibroblasts and haze in the cornea.28 The reduction in myofibroblast formation could
then reduce the development of a corneal scar, a very common sequela to equine corneal
ulceration. Another approach would be to deliver fibroblast growth factor (FGF2) gene with
AAV in the face of a developed corneal scar or chronic corneal ulcer to reduce the
established corneal scar. FGF2 has been shown to revert myofibroblasts to corneal fibroblast
using an in vitro model.30 Additional possibilities include modification of cytokine
production in the cornea. For example Morrison et al., used an AAV vector to increase
IL-10 in the lung of pigs with Actinobacillus pleuropneumoniae and found a reduction in
mortality and morbidity due to the decrease in macrophage activation which typically leads
to significant lung pathology.31 In cases of severe equine infectious keratitis, specifically
where keratomalacia is present, the immune response is fulminant and possibly over
stimulated. Delivering a therapeutic gene to increase expression of IL-10 could reduce the
immune response and if so, have clinical relevance. Greenberger et al., used an AAV vector
to increase IL-12 gene expression in tracheal epithelial cells of mice infected with
Klebsiella. IL-12, a pro-inflammatory cytokine stimulates an immune response. In certain
cases of equine corneal disease there appears to be a lack of an immune response. As a result
these cases can take months to heal and may require surgical intervention to aid in the
process. An AAV vector which could introduce an IL-12 gene to increase an immune
response may be of benefit. The advantages of gene therapy by delivering a gene or gene
products such as Flt23K, endostatin, kringle-5 domain of plasminogen, angiostatin, IL12,
IL10 etc. to reduce corneal neovascularization has been demonstrated using experimental
animal models.32 Additionally, gene therapy has huge potential for developing vaccines by
delivering DNA encoding for HSV-1 glycoproteins, such as glycoprotein (g) D, gB1, or a
cocktail of glycoproteins in an effort to increase immunity against HSV-induced ocular
keratitis.32 This same biotechnology has the potential to be applied to equine patients
inflicted with equine herpes keratitis.
To our knowledge, this is the first study to demonstrate that AAV5 can effectively transduce
ECFs, making AAV-mediated gene therapy a plausible method for treatment of equine
corneal disease.
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Light microscopy images of both ECFs alone and ECFs after application of AAV5 at two
time points (24 hrs and 48 hrs post application). All images demonstrate the classic normal,
spindle shape morphology of ECFs. ECFs alone at 24 hrs (A), ECFs + AAV5, 24 hrs after
application of AAV5 (B), ECFs alone at 48 hrs (C), and ECFs + AAV5, 48 hrs after
application of AAV5 (D). Calibration bar is 100 microns.
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Percent viability of control ECFs and ECFs transduced with AAV5 over three time points: 8
hrs, 24 hrs and 48 hrs after AAV5 application.
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Panels A–C demonstrate the successful transduction of ECF by AAV5 as evidenced by the
expression of EGFP demonstrating the classic spindle shape cellular morphology. The ECF
nuclei are stained by blue by DAPI. Panel D shows the quantification of the data using
Image J software and expressed as percent transduction efficiency.
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